Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised PatientsMarta Francesca Di Pasquale, Milena Encheva, Simone Aranha Nouér et al.|Clinical Infectious Diseases|2018Cited by 256
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Anthony Rodgers et al.|The Lancet HIV|2018Cited by 145
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Christine Katlama, Jean‐Michel Molina et al.|The Lancet HIV|2023Cited by 31
Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumoniaForest W. Arnold, Jordi Rello, Gustavo Lopardo et al.|Respiratory Medicine|2018Cited by 23